תקציר
In this study we present the effects of nilotinib and dasatinib on telomerase activity and regulation. Nilotinib and dasatinib strongly reduced telomerase activity in BCR-ABL-positive (K562) and BCR-ABL-negative (HL60) cells, demonstrating that their effect on telomerase activity is uncoupled from their effect on BCR-ABL. Nilotinib and dasatinib caused a substantial decrease in hTERT mRNA expression. Phospho-Sp1 regulates hTERT transcription. We detected a considerable decrease in Sp1 nuclear expression and binding to the hTERT promoter following exposure to the drugs. We also detected a reduction in Map kinase, known to phosphorylate Sp1. Telomerase is also activated and translocated to the nucleus when phosphorylated by AKT. We detected a decrease in phospho-AKT and a reduction in the nuclear expression of hTERT following exposure to nilotinib and dasatinib.In conclusion, we provide evidence for transcriptional and post-translational inhibition of telomerase by nilotinib and dasatinib which is not necessarily mediated via known targets of these tyrosine kinase inhibitors.
| שפה מקורית | אנגלית |
|---|---|
| עמודים (מ-עד) | 223-231 |
| מספר עמודים | 9 |
| כתב עת | Cancer Letters |
| כרך | 323 |
| מספר גיליון | 2 |
| מזהי עצם דיגיטלי (DOIs) | |
| סטטוס פרסום | פורסם - 28 אוק׳ 2012 |
| פורסם באופן חיצוני | כן |
טביעת אצבע
להלן מוצגים תחומי המחקר של הפרסום 'Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells'. יחד הם יוצרים טביעת אצבע ייחודית.פורמט ציטוט ביבליוגרפי
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver